CRB-701
Nectin-4 expressing solid tumors (e.g., Cervical Cancer, HNSCC, mUC)
Key Facts
About Corbus Pharmaceuticals
Corbus Pharmaceuticals is a clinical-stage biotech focused on developing innovative treatments for cancer and obesity, two of the most pressing global health challenges. Its strategy centers on optimizing known therapeutic modalities: a next-generation Nectin-4-targeting ADC (CRB-701) designed to improve upon first-generation toxicity, and a peripherally-restricted CB1 inverse agonist (CRB-913) aimed at achieving weight loss without central nervous system side effects. The company has advanced both lead assets into Phase 1 clinical trials, secured Fast Track designation for CRB-701 in specific cancers, and is positioning itself in multi-billion dollar markets with high unmet need.
View full company profile